It does seem logical to consider... if Azer Cell goes so well with patients who have failed so many lines, then surely it will go well at first line, surely they will just move it up to be first in line. But this is just how it goes in clinical trials. At whatever level the clinical trials is designed at (first in line, second iin line etc) that is where it goes when it gets commericalised.
IMU Price at posting:
4.1¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)